Therapeutic potential of perineural injection for temporomandibular joint pain, dysfunction and musculoskeletal ultrasound findings in rheumatoid arthritis patients

Elshoura, Hanan M.; Saber, Nayera Z.; Elwy, Mohamed; ABDEL-HAKIM, M.

doi:10.1016/j.ejr.2019.08.004

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These were in accordance with previous studies that assessed efficacy of NP for carpal tunnel syndrome and other musculoskeletal problems [27][28][29]. These indicated that NP procedure for MP was a simple, easy, safe and minimally invasive procedure [11,13,[28][29][30][31].…”

Section: Discussionsupporting

confidence: 90%

Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series

Saba

2022

Egypt J Neurosurg

View full text Add to dashboard Cite

Background Meralgia paresthetica is an entrapment neuropathy. Neuropathic pain was reported to be improved by using neural prolotherapy. Aim of the research was to assess and evaluate the short-term efficacy of neural prolotherapy on relieving pain, paresthesia and improving function and quality of life of patients with meralgia paresthetica. The study included 19 lower limbs with idiopathic meralgia paresthetica obtained from 15 patients. Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. All patients were evaluated for outcome measures twice, at baseline visit and at follow-up visit four weeks after the injection which included: patient assessment of overall symptoms of meralgia paresthetica, patient assessment of meralgia paresthetica pain, patient assessment of meralgia paresthetica paresthesia and patient assessment of meralgia paresthetica effect on function and quality of life using visual analogue scale. Results There was a statistically significant improvement in the visual analogue scale of patient assessment of overall meralgia paresthetica symptoms, patient assessment of meralgia paresthetica pain, patient assessment of meralgia paresthetica paresthesia and patient assessment of meralgia paresthetica effect on function and quality of life when the findings at the postinjection visit were compared to the preinjection assessment among all patients. All the patients tolerated the injection procedure-induced pain. All the patients experienced immediate postinjection relieve of the meralgia paresthetica pain. At the postinjection assessment visit, all patients were satisfied with the procedure. There were 12 lower limbs (63.2%) from 10 patients (66.6%) that showed improvement and recovery. Two patients of them had bilateral meralgia paresthetica. There was no patient withdrawal, and no patients were lost to follow-up. There was one lower limb (5.3%) from one patient (6.7%) who had bruises at the injection sites that resolved within few days after the procedure. Conclusions Neural prolotherapy is easy, safe, tolerable, effective and successful in treatment of meralgia paresthetica. It is effective in relieving pain, paresthesia and improving function and quality of life of patients with meralgia paresthetica. Neural prolotherapy injection should be included in the conservative treatment armamentarium of meralgia paresthetica. Trial registration : NCT04499911. Registered 5 August 2020—retrospectively registered.

show abstract

Section: Discussionsupporting

confidence: 90%

Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series

Saba

2022

Egypt J Neurosurg

View full text Add to dashboard Cite

show abstract

Subcutaneous injections of dextrose in musculoskeletal pain, a potential therapeutic intervention: scoping review

Arias-Vázquez,

Arcila-Novelo,

Guzzardo

et al. 2024

Pain Management

View full text Add to dashboard Cite

Efficacy of neural prolotherapy versus local corticosteroid soft tissue injection for treatment of chronic anserine bursitis: a prospective randomized clinical trial

Saba

2022

Ain-Shams J Anesthesiol

View full text Add to dashboard Cite

Background Anserine bursitis is characterized by the presence of spontaneous pain with tenderness at the inferomedial aspect of the knee joint. Neural prolotherapy aims to relieve pain of a variety of chronic musculoskeletal disorders. The study aim was to explore the short-term efficacy of neural prolotherapy (subcutaneous perineural injection of dextrose 5% solution) versus local corticosteroid injection for pain relief and improvement of function in patients with chronic anserine bursitis. The enrolled patients were randomly assigned to receive neural prolotherapy (subcutaneous perineural injection of dextrose 5% solution) (neural prolotherapy group) or a single local soft tissue injection of corticosteroid (corticosteroid group). Outcome measures included Western Ontario McMasters Universities osteoarthritis index, assessment of overall anserine bursitis pain severity using the visual analogue scale, patient’s global assessment of anserine bursitis severity using the visual analogue scale, and clinical assessment for the presence of tenderness on the anserine bursa region. Patients were evaluated before injection and after intervention by 4 weeks. Results The study included 67 lower limbs from 43 patients with chronic anserine bursitis. No significant differences were found between both treatment groups regarding all assessed parameters at the start of the study. After 4 weeks, within-group analysis showed that there was a statistically significant improvement in Western Ontario McMasters Universities osteoarthritis index and its subscales (P ≤ 0.0001), overall anserine bursitis pain severity (P ≤ 0.0001), and patient’s global assessment of anserine bursitis severity (P ≤ 0.0001), as well as there was significant improvement regarding the presence of tenderness at the anserine bursa region in both groups in comparison to the preinjection assessment. At the postinjection assessment, between-group analysis showed that there were no significant differences regarding all assessed outcome parameters. All patients in both groups tolerated the injection procedure and were satisfied with the procedure. There was no significant difference between the two groups regarding patients’ satisfaction to the procedure results. Improvement was achieved in 86.4% of patients included in the neural prolotherapy group versus 95.2% of patients included in the corticosteroid group. Conclusions Neural prolotherapy was effective in relieving pain, improving local tenderness and function in patients with chronic anserine bursitis similar to local corticosteroid injection. Trial registration ClinicalTrials.gov, registration number: NCT04509440. Registered 12 August 2020—Retrospectively registered,

show abstract

Therapeutic potential of perineural injection for temporomandibular joint pain, dysfunction and musculoskeletal ultrasound findings in rheumatoid arthritis patients

Cited by 3 publications

References 26 publications

Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series

Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series

Subcutaneous injections of dextrose in musculoskeletal pain, a potential therapeutic intervention: scoping review

Efficacy of neural prolotherapy versus local corticosteroid soft tissue injection for treatment of chronic anserine bursitis: a prospective randomized clinical trial

Contact Info

Product

Resources

About